Retatrutide is a GGG tri-agonist that uniquely targets GLP-1 and GIP receptors, similar to standard GLP-1 agonists, but also activates the glucagon receptor. This additional receptor interaction enhances glucagon production, leading to the breakdown of stored fats and glycogen, thereby increasing basal metabolism for more consistent fat loss. Its actions on GLP-1 and GIP receptors promote delayed gastric emptying and appetite control, providing a comprehensive approach to obesity research distinct from older GLP-1 agonists. Bacteriostatic water, alcohol wipes, and syringes included.